Page Image

Breast Cancers Today

Breast Cancers Today features breaking news, commentary, expert interviews, and more updates to inform healthcare professionals on the latest research and best clinical practices in the breast cancer space.

HER2
Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

Dr. Sara Nunnery, director of breast cancer research at Tennessee Oncology, discusses the evolving classification of HER2-low and HER2-ultralow breast cancer, and the clinical implications of the DESTINY-Breast06 trial. She explains how precise pathology reporting is key to identifying eligible patients and offers insights into how Enhertu (trastuzumab deruxtecan) is changing treatment decisions in HR-positive, HER2-low metastatic breast cancer.

Advertisement

Latest News

Expert Interviews

Advertisement
Editorial Board

Advertisement